Alterity Therapeutics Ltd. ATHE
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Alterity Therapeutics Ltd. (ATHE) is a healthcare company listed in the US with a market value of about $36M. In fiscal year 2025 it had revenue of $5M and net income of -$8M, a net margin of -150.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
A discounted cash flow model with moderate assumptions puts its intrinsic value about 85% below the current price.
About Alterity Therapeutics
Alterity Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $4M in 2016 to $5M in 2025, growth of about 4.2% a year. It was profitable in 5 of the last 10 years in our data.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $3M | — | — | — | — | — | $2M | $2M | $4M |
| Net income | -$8M | -$13M | $9M | $9M | $11M | $9M | $9M | -$6M | -$6M | -$6M |
| Free cash flow | — | -$8M | -$13M | -$9M | -$13M | -$6M | -$10M | -$5M | -$5M | -$6M |
| EPS (diluted) | $-0.44 | $-0.70 | $0.50 | $0.49 | $0.63 | $0.51 | $0.47 | $-0.34 | $-0.32 | $-0.32 |
| Net margin | -150.2% | -446.0% | — | — | — | — | — | -248.5% | -239.0% | -157.9% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Alterity Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 85% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alterity Therapeutics pay a dividend?
Not currently.
Is Alterity Therapeutics a good stock to buy?
We do not give buy or sell advice. Alterity Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.